- SyVento BioTech has entered a strategic partnership with Kymos Group to combine their CDMO and CRO capabilities.
- The collaboration will provide end-to-end solutions for RNA-based therapeutics, including GMP manufacturing, bioanalytical testing, and CMC services.
SyVento BioTech has announced a strategic partnership with Kymos Group aimed at delivering comprehensive solutions for RNA-based therapeutics. The collaboration combines SyVento’s preclinical and clinical drug development, liposomal and LNP technologies, and GMP manufacturing expertise with Kymos’ advanced bioanalytical and CMC services under GCP, GLP, GxP, and GMP standards.
The partnership focuses on supporting RNA therapeutics, including mRNA, oligonucleotides, lipids, and LNPs. By integrating manufacturing and analytical capabilities, the companies aim to provide a seamless development pathway from early-stage research to clinical and commercial batches.
Through this alliance, SyVento and Kymos intend to accelerate the development of novel RNA therapies, leveraging each company’s technical expertise to meet industry standards and regulatory requirements efficiently.
